Get the Stockscreener App
1.02
2.00%
0.02
Pmv Pharmaceuticals Inc stock is traded at $1.02, with a volume of 89,356.
It is up +2.00% in the last 24 hours and down -19.05% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
See More
Previous Close:
$1.00
Open:
$0.99
24h Volume:
89,356
Relative Volume:
0.70
Market Cap:
$49.44M
Revenue:
-
Net Income/Loss:
$-51.47M
P/E Ratio:
-1.02
EPS:
-1
Net Cash Flow:
$-47.50M
1W Performance:
+17.24%
1M Performance:
-19.05%
6M Performance:
-36.25%
1Y Performance:
-36.65%
1-Day Range:
$0.952
$1.04
1-Week Range:
$0.832
$1.05
52-Week Range:
$0.821
$2.26
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6664
Address
ONE RESEARCH WAY, PRINCETON
Compare PMVP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.02 | 49.44M | 0 | -51.47M | -47.50M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
PMVP stock touches 52-week low at $1.01 amid market challenges - Investing.com Australia
PMV Pharmaceuticals stock hits 52-week low at $1.2 amid market shifts - Investing.com
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HC Wainwright Reiterates “Buy” Rating for PMV Pharmaceuticals (NASDAQ:PMVP) - Defense World
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
PMVP stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
PMVP stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing - Nasdaq
PMV Pharmaceuticals Reports Progress in Clinical Trials - TipRanks
PMV Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com South Africa
PMV Pharmaceuticals stock hits 52-week low at $1.32 - Investing.com
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
PMV Pharmaceuticals (PMVP) Expected to Announce Quarterly Earnings on Thursday - Defense World
3 US Penny Stocks To Consider In February 2025 - simplywall.st
PMV Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection - Pulse 2.0
PMVP Stock Sees Surge of Approximately 2.86% in Last Five Days - Knox Daily
Catalio Capital Management Joins $15 Million Series A for Perceive Pharma - citybiz
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection - PR Newswire
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Significant Drop in Short Interest - MarketBeat
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results - br.ADVFN.com
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
PMVP's Top Executives Set to Reveal Latest Oncology Developments at Major Healthcare Conferences - StockTitan
US Penny Stocks To Watch In January 2025 - Simply Wall St
Assenagon Asset Management S.A. Reduces Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Barclays PLC Trims Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Barclays PLC Trims Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Jane Street Group LLC Sells 89,957 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Jane Street Group LLC Sells 18,128 Shares of New Found Gold Corp. (NYSE:NFGC) - Defense World
PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges - Investing.com India
PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Barclays PLC Sells 434,704 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Barclays PLC Cuts Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer - The Manila Times
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial - Nature
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):